Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)
Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%
Latigo Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.50M | – |
| Q2 FY2026 | Jun 30, 2026 | $21.23M | – |
| Q3 FY2025 | Sep 30, 2025 | $22.10M | – |
| Q2 FY2025 | Jun 30, 2025 | $22.92M | – |
See a number that looks wrong?